4D Molecular Therapeutics (NASDAQ:FDMT) Sees Strong Trading Volume – Here’s Why

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) saw an uptick in trading volume on Monday. Approximately 733,855 shares traded hands during trading, a decline of 12% from the previous session’s volume of 837,695 shares. The stock last traded at $14.1280 and had previously closed at $14.47.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Cantor Fitzgerald raised 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 target price on the stock in a research report on Monday, September 14th. B. Riley Financial reissued a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.56.

4D Molecular Therapeutics Price Performance

The company’s 50 day moving average price is $13.17 and its 200-day moving average price is $11.08. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The company has a market cap of $802.31 million, a price-to-earnings ratio of -5.53 and a beta of 2.74.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The company had revenue of $3.78 million for the quarter, compared to analysts’ expectations of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. On average, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Transactions at 4D Molecular Therapeutics

In related news, insider David Kirn sold 58,333 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $13.90, for a total value of $810,828.70. Following the transaction, the insider directly owned 767,486 shares in the company, valued at $10,668,055.40. This represents a 7.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 134,570 shares of company stock worth $1,743,197. Corporate insiders own 7.90% of the company’s stock.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of FDMT. Persistent Asset Partners Ltd bought a new stake in shares of 4D Molecular Therapeutics during the second quarter worth about $1,936,000. Deutsche Bank AG bought a new stake in 4D Molecular Therapeutics during the 2nd quarter worth approximately $9,456,000. Dimensional Fund Advisors LP grew its position in 4D Molecular Therapeutics by 77.3% during the first quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock valued at $4,863,000 after acquiring an additional 227,982 shares during the last quarter. Exome Asset Management LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth about $1,216,000. Finally, Bank of America Corp DE increased its stake in shares of 4D Molecular Therapeutics by 17.0% during the first quarter. Bank of America Corp DE now owns 974,173 shares of the company’s stock valued at $9,070,000 after purchasing an additional 141,582 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.